DE69305348D1 - Proteintyrosinphosphatase alpha - Inhibitoren zur Tumorbehandlung - Google Patents

Proteintyrosinphosphatase alpha - Inhibitoren zur Tumorbehandlung

Info

Publication number
DE69305348D1
DE69305348D1 DE69305348T DE69305348T DE69305348D1 DE 69305348 D1 DE69305348 D1 DE 69305348D1 DE 69305348 T DE69305348 T DE 69305348T DE 69305348 T DE69305348 T DE 69305348T DE 69305348 D1 DE69305348 D1 DE 69305348D1
Authority
DE
Germany
Prior art keywords
protein tyrosine
tyrosine phosphatase
tumor treatment
alpha inhibitors
phosphatase alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69305348T
Other languages
English (en)
Other versions
DE69305348T2 (de
Inventor
Catherine Jane Pallen
Xin Min Zheng
Yue Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Molecular and Cell Biology
Original Assignee
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore filed Critical National University of Singapore
Publication of DE69305348D1 publication Critical patent/DE69305348D1/de
Application granted granted Critical
Publication of DE69305348T2 publication Critical patent/DE69305348T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69305348T 1992-07-10 1993-07-09 Proteintyrosinphosphatase alpha - Inhibitoren zur Tumorbehandlung Expired - Fee Related DE69305348T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929214754A GB9214754D0 (en) 1992-07-10 1992-07-10 Tumour treatment
PCT/CA1993/000285 WO1994001119A1 (en) 1992-07-10 1993-07-09 INHIBITORS OF PROTEIN TYROSINE-PHOSPHATASE α FOR TREATMENT OF TUMORS

Publications (2)

Publication Number Publication Date
DE69305348D1 true DE69305348D1 (de) 1996-11-14
DE69305348T2 DE69305348T2 (de) 1997-02-20

Family

ID=10718558

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69305348T Expired - Fee Related DE69305348T2 (de) 1992-07-10 1993-07-09 Proteintyrosinphosphatase alpha - Inhibitoren zur Tumorbehandlung

Country Status (5)

Country Link
EP (1) EP0648123B1 (de)
AT (1) ATE143808T1 (de)
DE (1) DE69305348T2 (de)
GB (1) GB9214754D0 (de)
WO (1) WO1994001119A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682905B1 (en) 1990-07-11 2004-01-27 New York University Receptor-type phosphotyrosine phosphatase-alpha
US20050036999A1 (en) 1990-07-11 2005-02-17 New York University Novel receptor-type phosphotyrosine phosphatase-alpha
US5861266A (en) * 1994-02-28 1999-01-19 New York University Treatment of diabetes mellitus and insulin receptor signal transduction
GB9411671D0 (en) * 1994-06-10 1994-08-03 Univ Singapore Tumor diagnosis and prognosis
GB9516059D0 (en) * 1995-08-04 1995-10-04 Medical Res Council Novel genes and proteins
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US6039569A (en) * 1997-08-12 2000-03-21 Jeneric/Pentron Incorporated Fiber-reinforced dental structures and method of manufacture thereof
CN102108365A (zh) * 2009-12-29 2011-06-29 上海新号源生物科技有限公司 一组恶性肿瘤中突变PTPα基因及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710469A (en) * 1986-05-02 1987-12-01 Merck & Co., Inc. Novel phosphotyrosyl protein phosphatase
EP0627489B1 (de) * 1990-03-14 1998-09-02 Washington Research Foundation Methode und Zusammensetzungen zur Behandlung von bösartigen Entartungen, die in Zusammenhang mit einer Proteinkinase stehen
CA2087008A1 (en) * 1990-07-11 1992-01-12 Joseph Schlessinger Novel receptor-type phosphotyrosine phosphatase

Also Published As

Publication number Publication date
EP0648123A1 (de) 1995-04-19
ATE143808T1 (de) 1996-10-15
GB9214754D0 (en) 1992-08-19
WO1994001119A1 (en) 1994-01-20
EP0648123B1 (de) 1996-10-09
DE69305348T2 (de) 1997-02-20

Similar Documents

Publication Publication Date Title
BR9805544A (pt) Uso de um composto.
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
DE69030825D1 (de) Katheter zur gleichmässigen Verteilung von therapeutischen Flüssigkeiten
NO985652D0 (no) Anvendelse av naaladaseinhibitorer ved behandling av kreft
CY1105618T1 (el) Δικυκλικες ετεροαρωματικες ενωσεις ως αναστολεις της κινασης τυροσινης πρωτεϊνης
TR200001312T2 (tr) Benzotiyazol protein tirozin kinaz önleyicileri.
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
BR9910511A (pt) Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento
DK130387A (da) Transglutaminase inhibitorer
SE8104625L (sv) Anvending av aromatas-hemmare for profylax och terapi av prostatahyperplasi
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
ID21698A (id) Karboksamida-karboksamida aril bisiklik dan penggunaan terapinya
DE69534908D1 (de) Verwendung von statin zur behandlung von hauterkrankungen
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
DE69305348D1 (de) Proteintyrosinphosphatase alpha - Inhibitoren zur Tumorbehandlung
DE68903378D1 (de) Hemmung der zellenadhaesion.
GR3029490T3 (en) Use of leflunomid for the inhibition of tumor necrosis factor alpha.
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
NO20005680L (no) Kombinasjoner av protein-farnesyltransferase og HMG CoA reduktase inhibitorer og anvendelse derav for behandling av cancer
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
ES545155A0 (es) Procedimiento para la obtencion de (pirrol-1-il)-fenil-dihi-dropiridazinona
ES2072280T3 (es) Enzimas catabolicas para la induccion del factor de necrosis tumoral (tnf).
NO913995L (no) Inhibitorer for dannelse av tumornekrosefaktor samt fremgangsmaate og anvendelse derav
ATE84416T1 (de) Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hyperthrophie.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: INSTITUTE OF MOLECULAR AND CELL BIOLOGY, SINGAPUR/

8339 Ceased/non-payment of the annual fee